Lyell Immunopharma, Inc.
Lyell develops next-generation CAR T-cell therapies for hematologic malignancies and solid tumors.
8-KSep 10Latest SEC filing, period to Sep 10
Sep 10Latest story
September 2026
August 2026
Sign inSign inLyell develops next-generation CAR T-cell therapies for hematologic malignancies and solid tumors.